EZH1
ENSG00000108799
Target class
Epigenetic regulator
Chromosome
17
- Chemical probe available
- Yes
- Target name
- EZH1
- Gene name
- Enhancer of zeste 1 polycomb repressive complex 2 subunit
- Gene symbol
- EZH1
- Protein name
- Histone-lysine N-methyltransferase EZH1 (EC 2.1.1.356) (ENX-2) (Enhancer of zeste homolog 1)
- KIAA0388
- KMT6B
- Gene biotype
- Protein coding
- Gene family
- Histone lysine methyltransferases|Myb/SANT domain containing|Polycomb repressive complex 2|SET domain containing|MicroRNA protein coding host genes
- Target class
- Epigenetic regulator
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 143.03
- Tissue specificity (Gini)
- 0.307
- Tissue specificity (tau)
- 0.663
- KEGG gene identifiers
- hsa:2145
- Reactome pathways
- R-HSA-212300
- Protein interaction confidence
- 0.897432
- Protein interaction partners
- 44
- End position
- 42745060
- Start position
- 42700270
- Chromosome
- 17
- Strand
- Reverse
- Nucleus . Note=Colocalizes with trimethylated 'Lys-27' of histone H3.
- Nucleoplasm
Publication evidence
- PubMed 19026781
- Tissue specificity (tau)
- 0.662547
- Expression inequality (Gini)
- 0.307086
Expression in transcripts per million
- Brain - Cerebellar Hemisphere
- 143.03
- Brain - Cerebellum
- 134.07
- Nerve - Tibial
- 114.77
- Ovary
- 100.64
- Cervix - Ectocervix
- 89.72
Expression in transcripts per million
- Brain - Cerebellar Hemisphere143.03
- Brain - Cerebellum134.07
- Nerve - Tibial114.77
- Ovary100.64
- Cervix - Ectocervix89.72
- Cervix - Endocervix88.91
- Uterus88.87
- Fallopian Tube80.85
- Artery - Tibial76.37
- Adipose - Subcutaneous75.72
- Spleen65.79
- Vagina64.9
- Breast - Mammary Tissue64.54
- Esophagus - Gastroesophageal Junction64.53
- Thyroid64.18
- Esophagus - Muscularis61.72
- Colon - Sigmoid57.14
- Artery - Aorta56.79
- Artery - Coronary55.4
- Bladder54.8
- Lung53.96
- Prostate51
- Pituitary50.68
- Adipose - Visceral (Omentum)49.26
- Small Intestine - Terminal Ileum47.7
And 29 more, listed on the interactive page.
Biological processes
- GO:0009653
- GO:0005634
- GO:0005654
- GO:0035098
- GO:0003682
- GO:0005515
- GO:0016279
- GO:0031491
- GO:0046976
- GO:0140693
- GO:0140951
Related records
Trials (110)
- A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer
- A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia
- A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
- A Food Effect Study of SHR2554 on Healthy Chinese Male Adult Subjects
- A Itraconazole Effect Study of SHR2554 on Healthy Chinese Adult Subjects
- A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
- A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
- A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma
- A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
- A Relative Bioavailability Study of Different Processes of SHR2554 Tablets in Healthy Adult Subjects
- A Rifampin Effect Study of SHR2554 on Healthy Chinese Adult Subjects
- A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
- A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)
- A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
- A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
- A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer
- A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
- A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma
- A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
Drugs (4)
- Tazemetostat
- Tulmimetostat
- Valemetostat
- Zeprumetostat